EBMT Distinguished Interview | Professor Jun Ma Reflects on 42 Years with EBMT

EBMT Distinguished Interview | Professor Jun Ma Reflects on 42 Years with EBMT

From April 14 to 17, 2024, the 50th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) was grandly held in Glasgow, UK. This year marks the 50th anniversary of EBMT, and the event brought together leaders in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. Together, they reviewed the remarkable achievements in the field of blood and marrow transplantation over the past 50 years and explored future prospects for patient management. At the conference, our magazine's onsite reporters specially invited Professor Jun Ma, a leading figure in hematology from the Harbin Institute of Hematological Oncology, to recount the history of hematopoietic stem cell transplantation and share his profound insights from attending the EBMT conferences for over four decades.
Professor Jianmin Ma: Research Progress on Ocular Adnexal Lymphoma | Inaugural Academic Forum of Ocular Lymphoma Collaboration Group

Professor Jianmin Ma: Research Progress on Ocular Adnexal Lymphoma | Inaugural Academic Forum of Ocular Lymphoma Collaboration Group

On March 30, 2024, the inaugural academic forum of the Ocular Lymphoma Collaboration Group was successfully held in Beijing, hosted by Peking University Health Science Center affiliated Beijing Tongren Hospital, the China Health Science and Technology Promotion Association, Beijing Public Health Science Popularization Association, and the Beijing Chen Jumei Public Welfare Foundation. The event, organized by the Cell Immunotherapy Professional Committee of the China Health Science and Technology Promotion Association, saw active exchanges and lively discussions among renowned domestic and international experts and scholars on the latest developments and hot topics in the diagnosis and treatment of ocular lymphoma. Professor Jianmin Ma, the head of the collaboration group and chairman of the conference from Peking University Health Science Center affiliated Beijing Tongren Hospital, was interviewed by "Oncology Frontier - Hematology Frontier" where he shared insights into the establishment of the Ocular Lymphoma Collaboration Group, research progress on ocular adnexal lymphoma, and treatment strategies.
Professor Yi Luo: Interpretation of the Chinese Expert Consensus on Prevention and Treatment of Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (2023 Edition)

Professor Yi Luo: Interpretation of the Chinese Expert Consensus on Prevention and Treatment of Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (2023 Edition)

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a primary treatment for malignant blood diseases, with its numbers increasing annually. China is a region with moderate prevalence of hepatitis B virus (HBV), with approximately 5% to 6% of the population carrying hepatitis B surface antigen (HBsAg), and an annual incidence rate of about 1%. Patients positive for HBsAg or with past HBV infection are at risk of HBV reactivation during immunosuppressive therapy, chemotherapy, or monoclonal antibody-targeted therapy, with a higher risk during allo-HSCT. However, there is currently a lack of standardized clinical consensus or guidelines for the prevention and treatment of HBV reactivation after allo-HSCT in China. To address this, the Hematopoietic Stem Cell Application Group of the Hematology Branch of the Chinese Medical Association formulated and released the "Chinese Expert Consensus on Prevention and Treatment of Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (2023 Edition)." At the recently concluded 13th National Congress of Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, Professor Yi Luo from the , as the principal expert of the consensus, provided an interpretation of the consensus, aiming to provide clinical guidance for hematologists, hematopoietic stem cell transplantation sub-specialists, and related physicians.
2024 EBMT 5 Minutes | Professor Pan Jing: Advances in Acute Lymphoblastic Leukemia Research

2024 EBMT 5 Minutes | Professor Pan Jing: Advances in Acute Lymphoblastic Leukemia Research

The European Society for Blood and Marrow Transplantation (EBMT) annual meeting is one of the most influential international academic conferences in the field of hematology. The 50th EBMT annual meeting (EBMT 2024) was held from April 14 to April 17 in Glasgow, UK, bringing together nearly 6,000 experts and scholars from around the world to discuss the latest research on hematopoietic stem cell transplantation and cell therapy. In this issue, "Oncology Frontier - Hematology Frontier" has specially invited Director Pan Jing from Beijing Gaobo Hospital to comment on two studies in the field of acute lymphoblastic leukemia (ALL).
EBMT 2024 | Entering the Golden Age – Grand Opening of the 50th European Society for Blood and Marrow Transplantation Annual Meeting

EBMT 2024 | Entering the Golden Age – Grand Opening of the 50th European Society for Blood and Marrow Transplantation Annual Meeting

From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in the renowned city of Glasgow, United Kingdom. This year marks the 50th anniversary of EBMT's establishment, and the conference brought together leading figures in the field of hematopoietic stem cell transplantation, along with over 6,000 hematologists and experts from around the globe. Together, they reviewed the remarkable achievements made in the field of blood and marrow transplantation over the past 50 years and explored future prospects for patient management.
Professor Chunyan Sun: Application of Peripheral Blood Circulating Plasma Cell Detection in Multiple Myeloma (MM) | The 15th Academic Conference of the Chinese Medical Association’s Experimental Diagnosis Hematology Branch and the First Academic Conference on Rare Blood Diseases

Professor Chunyan Sun: Application of Peripheral Blood Circulating Plasma Cell Detection in Multiple Myeloma (MM) | The 15th Academic Conference of the Chinese Medical Association’s Experimental Diagnosis Hematology Branch and the First Academic Conference on Rare Blood Diseases

From March 23rd to 24th, 2024, the 15th Academic Conference of the Chinese Medical Association's Experimental Diagnosis Hematology Branch and the First Academic Conference on Rare Blood Diseases, hosted by…
Professor Chengcheng Fu: The Current Status and Future Trends of CAR-T Therapy for Multiple Myeloma | The 7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematologic Malignancies and Immunity Summit Forum

Professor Chengcheng Fu: The Current Status and Future Trends of CAR-T Therapy for Multiple Myeloma | The 7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematologic Malignancies and Immunity Summit Forum

From March 2nd to 3rd, 2024, the "7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematologic Malignancies and Immunity Summit Forum," hosted by the National Clinical Research Center for Blood Diseases at Peking University Institute of Hematology and Chinese Academy of Medical Sciences Peking Union Medical College Hospital, was successfully held in Beijing. Numerous domestic and international hematology experts shared the latest advances in the treatment of leukemia, coagulation diseases, and malignant hematologic disorders through keynote reports, paper discussions, case presentations, and expert symposiums. At the conference, Professor Chengcheng Fu from The First Affiliated Hospital of Soochow University gave an excellent presentation on the topic of "The Current Status and Future Trends of CAR-T Therapy for Multiple Myeloma." The content was compiled by "Oncology Watch - Hematology News" for the reference of readers.
EBMT Hot Review | Professor Depei Wu: PT-Cy Regimen for GVHD Prevention May Lead to T-Cell Diversity Deficiency, Significantly Impacting Efficacy and Safety

EBMT Hot Review | Professor Depei Wu: PT-Cy Regimen for GVHD Prevention May Lead to T-Cell Diversity Deficiency, Significantly Impacting Efficacy and Safety

Graft-versus-host disease (GVHD) is one of the major complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), exhibiting diverse clinical manifestations with prolonged course. Improper diagnosis and treatment can not only affect patients' quality of life but also have a significant impact on long-term survival. With the continuous improvement of modern transplant technology, patients' demand for post-transplant quality of life is increasing, emphasizing the importance of GVHD prevention and treatment. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT2024) was held in Glasgow, UK. On the second day of the conference, Leslie Kean and colleagues from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center in the United States orally presented a clinical study (Abstract No. GS02-02), suggesting that the post-transplant cyclophosphamide (PT-Cy) regimen, while effectively controlling unrelated donor GVHD, may increase the risk of grade 2 or higher infections. Through further large-scale T-cell receptor (TCR) sequencing (TCR-seq), researchers found that PT-Cy significantly reduces patients' TCR diversity, which may be a contributing factor to the higher incidence of infections. We are pleased to invite Professor Depei Wu from The First Affiliated Hospital of Soochow University to provide insightful commentary on this study.
EBMT China’s Voice | Professor Deyan Liu’s Team: Allogeneic Hematopoietic Stem Cell Transplantation Significantly Improves Survival Rates for Patients with Therapy-Related Myeloid Neoplasms

EBMT China’s Voice | Professor Deyan Liu’s Team: Allogeneic Hematopoietic Stem Cell Transplantation Significantly Improves Survival Rates for Patients with Therapy-Related Myeloid Neoplasms

Therapy-related myeloid neoplasms (t-MN) are a distinct type of myeloid tumor that occur after cytotoxic or radiation therapy. In the 2022 WHO classification of hematopoietic and lymphoid tissue tumors, these were termed secondary myeloid neoplasms, including those related to cytotoxic treatment and genetic susceptibility. Compared to newly diagnosed AML, therapy-related AML (t-AML) has a poorer prognosis, including poor chemotherapy response, low rates of remission, and overall lower survival rates. From April 14-17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT 2024) held its annual meeting in Glasgow, UK. Dr. Yan Shu from the team of Professor Deyan Liu at Hebei Yanda Lu Daopei Hospital presented a clinical study (abstract number 391) that demonstrated allogeneic hematopoietic stem cell transplantation significantly improved survival rates in patients with t-MN.